Characteristics of patients according to the arm of consolidation therapy
| Characteristics . | HDAraC: P1 arm (117 patients) . | TSC: P2 arm (120 patients) . |
|---|---|---|
| Age, y | 45 (18-50) | 46 (17-50) |
| Biology at diagnosis | ||
| WBC count, ×109/L | 12.6 (0.8-230) | 12.1 (0.6-206) |
| Hemoglobin level, g/L | 91 (33-149) | 90 (37-136) |
| Platelets, ×109/L | 59 (11-404) | 67 (9-346) |
| PB blasts, % | 43 (0-97) | 38 (0-98) |
| BM blasts, % | 70 (20-100) | 74 (20-100) |
| Clinical presentation | ||
| Hepatomegaly, % | 8 (7) | 6 (5) |
| Splenomegaly, % | 11 (9) | 11 (9) |
| CNS+, % | 0 (0) | 2 (2) |
| Bleeding, % | 32 (27) | 27 (23) |
| Fever, % | 38 (32) | 42 (35) |
| FAB classification | ||
| M0, % | 3 (3) | 6 (5) |
| M1, % | 18 (15) | 30 (25) |
| M2, % | 34 (29) | 28 (23) |
| M4, % | 23 (20) | 30 (25) |
| M5, % | 28 (24) | 17 (14) |
| M6, % | 4 (3) | 1 (1) |
| M7, % | 1 (1) | 2 (2) |
| Not performed, % | 6 (5) | 6 (5) |
| WHO PS, % | ||
| 0 | 47 (40) | 39 (32) |
| 1 | 62 (53) | 61 (51) |
| 2 | 8 (7)‡ | 20 (17)‡ |
| Cytogenetics | ||
| Favorable | 12 (11) | 19 (16) |
| Intermediate | 71 (61) | 72 (60) |
| Unfavorable | 28 (24)§ | 15 (13)§ |
| Failure | 5 (4) | 13 (11) |
| Not performed | 1 | 1 |
| Risk stratification | ||
| Favorable-risk group* | 32 (28) | 39 (32) |
| Poor-risk group† | 79 (66) | 67 (56) |
| Unclassified | 6 (6) | 14 (12) |
| Characteristics . | HDAraC: P1 arm (117 patients) . | TSC: P2 arm (120 patients) . |
|---|---|---|
| Age, y | 45 (18-50) | 46 (17-50) |
| Biology at diagnosis | ||
| WBC count, ×109/L | 12.6 (0.8-230) | 12.1 (0.6-206) |
| Hemoglobin level, g/L | 91 (33-149) | 90 (37-136) |
| Platelets, ×109/L | 59 (11-404) | 67 (9-346) |
| PB blasts, % | 43 (0-97) | 38 (0-98) |
| BM blasts, % | 70 (20-100) | 74 (20-100) |
| Clinical presentation | ||
| Hepatomegaly, % | 8 (7) | 6 (5) |
| Splenomegaly, % | 11 (9) | 11 (9) |
| CNS+, % | 0 (0) | 2 (2) |
| Bleeding, % | 32 (27) | 27 (23) |
| Fever, % | 38 (32) | 42 (35) |
| FAB classification | ||
| M0, % | 3 (3) | 6 (5) |
| M1, % | 18 (15) | 30 (25) |
| M2, % | 34 (29) | 28 (23) |
| M4, % | 23 (20) | 30 (25) |
| M5, % | 28 (24) | 17 (14) |
| M6, % | 4 (3) | 1 (1) |
| M7, % | 1 (1) | 2 (2) |
| Not performed, % | 6 (5) | 6 (5) |
| WHO PS, % | ||
| 0 | 47 (40) | 39 (32) |
| 1 | 62 (53) | 61 (51) |
| 2 | 8 (7)‡ | 20 (17)‡ |
| Cytogenetics | ||
| Favorable | 12 (11) | 19 (16) |
| Intermediate | 71 (61) | 72 (60) |
| Unfavorable | 28 (24)§ | 15 (13)§ |
| Failure | 5 (4) | 13 (11) |
| Not performed | 1 | 1 |
| Risk stratification | ||
| Favorable-risk group* | 32 (28) | 39 (32) |
| Poor-risk group† | 79 (66) | 67 (56) |
| Unclassified | 6 (6) | 14 (12) |
WBC indicates white blood cell; PB, peripheral blood; BM, bone marrow; CNS+, central nervous system involvement; FAB, French-American-British; and PS, performance status.
Included patients with favorable cytogenetics and CN-AML NPM1+ or CEBPA+wt FLT3-ITD.
Included patients with unfavorable cytogenetics and those with intermediate cytogenetics other than CN-AML NPM1+ or CEBPA+wt FLT3-ITD.
P = .03.
P = .03.